NCT06055894 A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
| NCT ID | NCT06055894 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Multiple Myeloma, Smoldering |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2023-09-20 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2023-09-20 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are going this to look at how butyrate levels change in participants' stool after they are on a plant-based diet or dietary supplements (omega-3, curcumin or probiotics) for 2 weeks. All participants will have smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). The researchers will compare how the different dietary changes affect butyrate levels in participants' stool.
Eligibility Criteria
Inclusion Criteria: * Confirmed prior diagnosis MGUS or of smoldering myeloma (any time prior). However, confirmation of diagnosis must be documented in their last local oncologist clinic note within 6 months prior to study enrollment. * Age ≥18 years * Willingness to comply with all study-related procedures * Physically able to complete requirements for the study or has someone to assist with the requirements (such as meal preparation, stool shipment and survey completion) * Interested in learning to cook plant-based recipes * Access to smart mobile phone or device with camera and ability to download Keenoa app * Be residing within the United States for the study duration. * English speaking or a family member or caregiver who speaks English and is able to assist with the surveys and phone based Keenoa app. Exclusion Criteria: * Taking any supplements other than vitamin D, iron, vitamin B12, potassium, magnesium, calcium or those needed for a medical indication must be reviewed by PI. If patient is on a supplement (including curcumin, probiotic, omega3) they must stop these for 2 weeks prior to enrollment on study. * Patients that already follow a whole foods plant based diet (ovo-lactovegetarian or processed junk food vegan diets are not excluded). This will be per research dietitian evaluation and discretion after nutrition screening. * Legume allergy * Severe allergies such as anaphylactic shock to peanuts and/or tree nuts, such as cashews * Concurrent participation in weight loss/dietary trials or defined programs (that require specified diets/supplements on the program). Patients on weight loss drugs are eligible. * Mental impairment leading to inability to cooperate * Enrollment onto any other therapeutic investigational study * Concurrent pregnancy * Patients on full dose anticoagulation * If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely * Current self-reported heavy alcohol use and is defined as \>5 drinks per day or \>15 drinks per week * Current self-reported illicit drug use (except inhaled marijuana, vaping or cigarette smoking or medical marijuana. * Has a condition requiring antibiotics within 14 days of study intervention administration. * Plan for travel during the study that would preclude adherence to prescribed diets * History of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted)
Contact & Investigator
Urvi A Shah, MD, MS
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT06055894 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma, Smoldering. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06055894 currently recruiting?
Yes, NCT06055894 is actively recruiting participants. Contact the research team at ShahNutrivention@mskcc.org for enrollment information.
Where is the NCT06055894 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT06055894 clinical trial?
NCT06055894 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Urvi A Shah, MD, MS at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 200 participants.